Who makes Argemone mexicana?

Argemone mexicana is developed by University of Bamako.

What development phase is Argemone mexicana in?

Argemone mexicana is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Argemone mexicana

University of Bamako · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Argemone mexicana
Also known as	traditional antimalarial
Sponsor	University of Bamako
Drug class	Non-Standardized Food Allergenic Extract [EPC]
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 1b Malaria Clinical Trial Using Argemone Mexicana in Healthy Adults in Mali (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Argemone mexicana CI brief — competitive landscape report
Argemone mexicana updates RSS · CI watch RSS
University of Bamako portfolio CI